NASDAQ:PTLA Portola Pharmaceuticals (PTLA) Stock Price, News & Analysis → America's #1 AI Dividend Stock Revealed (From The Oxford Club) (Ad) Free PTLA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$18.03▼$18.0350-Day Range$18.03▼$18.0352-Week Range$5.31▼$31.73VolumeN/AAverage Volume3.17 million shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Portola Pharmaceuticals alerts: Email Address Ad The Oxford ClubAmerica's #1 AI Dividend Stock RevealedIncome expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Portola Pharmaceuticals Stock (NASDAQ:PTLA)Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.Read More Ad The Oxford ClubAmerica's #1 AI Dividend Stock RevealedIncome expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. PTLA Stock News HeadlinesApril 15, 2023 | usnews.comPortola MiddleMarch 25, 2023 | sfgate.comFault lines in Portola ValleyMarch 23, 2023 | usnews.comPortola-Butler Continuation High SchoolFebruary 18, 2023 | yahoo.comPortola, United States - Weather Forecasts | Maps | News - Yahoo WeatherDecember 31, 2022 | forbes.comEagle PharmaceuticalsNovember 21, 2022 | markets.businessinsider.comBerman Tabacco Announces Class Action Settlement In Securities Litigation Involving Purchasers of Portola Pharmaceuticals, Inc. Common StockOctober 7, 2022 | investing.comPTLA_old Historical DataSeptember 29, 2022 | seekingalpha.comKPRX Kiora Pharmaceuticals, Inc.See More Headlines Receive PTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portola Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today6/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PTLA CUSIPN/A CIK1269021 Webwww.portola.com Phone650-246-7000FaxN/AEmployees324Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,660,000.00 Net Margins-232.73% Pretax MarginN/A Return on Equity-267.86% Return on Assets-54.66% Debt Debt-to-Equity Ratio4.77 Current Ratio4.87 Quick Ratio4.82 Sales & Book Value Annual Sales$116.64 million Price / Sales12.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book10.80Miscellaneous Outstanding Shares78,484,000Free FloatN/AMarket Cap$1.42 billion OptionableOptionable Beta2.32 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Mardi C. Dier (Age 55)Exec. VP, Chief Bus. Officer & CFO Dr. John T. Curnutte (Age 67)Exec. VP and Head of R&D Mr. J. Scott Garland M.B.A. (Age 50)MBA, Pres & CEO Cara MillerVP of Investor Relations and Corp. CommunicationsMr. John B. Moriarty Jr. (Age 51)Exec. VP, Gen. Counsel & Sec. Key CompetitorsCytokineticsNASDAQ:CYTKSummit TherapeuticsNASDAQ:SMMTOrganon & Co.NYSE:OGNApellis PharmaceuticalsNASDAQ:APLSBridgeBio PharmaNASDAQ:BBIOView All Competitors PTLA Stock Analysis - Frequently Asked Questions How were Portola Pharmaceuticals' earnings last quarter? Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) released its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.14. The biopharmaceutical company had revenue of $26.40 million for the quarter, compared to analyst estimates of $33.88 million. Portola Pharmaceuticals had a negative net margin of 232.73% and a negative trailing twelve-month return on equity of 267.86%. Portola Pharmaceuticals's revenue for the quarter was up 18.9% on a year-over-year basis. During the same period in the previous year, the business posted ($1.02) earnings per share. What other stocks do shareholders of Portola Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Amarin (AMRN), Exelixis (EXEL), NVIDIA (NVDA), Geron (GERN), ACADIA Pharmaceuticals (ACAD) and Aileron Therapeutics (ALRN). This page (NASDAQ:PTLA) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHistoric NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portola Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portola Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.